Alopres

Quick links to important sections

Alopres

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alopres

Quick Facts

Property Description
Active ingredient Amlodipine Besylate
Form Oral Tablet
Pharmacological class Calcium Channel Blocker (CCB)
Common use Supporting efficient cardiovascular function
Origin Synthetic Compound

Defining Alopres: Core Identity and Composition

Alopres is a trade name for a widely recognized, prescription-only medication whose single active ingredient is Amlodipine Besylate, which is the internationally non-proprietary name (INN) for the chemical entity. This medication is manufactured as a synthetic compound and is consistently administered as an oral tablet preparation.

The formulation of Amlodipine as a besylate salt is recognized for its stability and reliable absorption after ingestion via the oral route of administration. Amlodipine is clinically recognized for its use in supporting cardiovascular health by reducing high arterial pressure and preventing certain types of chest pain.

Alopres’ Pharmacological Classification and Type

Alopres is scientifically classified as a Calcium Channel Blocker (CCB), specifically falling into the dihydropyridine subgroup of cardiovascular agents. This classification identifies the drug as one that works by modulating the flow of calcium ions into the cells of the blood vessels.

The function of a dihydropyridine CCB is characterized by its greater selective action on vascular smooth muscle cells, which differentiates it from agents that primarily affect the heart’s electrical conduction system. Amlodipine functions as a long-acting vasodilator.

General Purpose of Amlodipine

The fundamental general purpose of Amlodipine is to support cardiovascular health through a process called peripheral vasodilation. By inhibiting the influx of calcium ions, the drug causes the blood vessels to relax and widen, directly reducing the overall resistance in the circulatory system. This consistent vascular relaxation primarily aims to reduce high arterial pressure and improve blood flow and oxygen supply to the heart muscle, supporting the general efficiency of the entire circulatory system.

Regulatory References

  1. NIH, MedlinePlus

What side effects are possible with Alopres?

Possible side effects and safety information

The safety profile of Alopres (Amlodipine) is characterized by documented adverse reactions classified by frequency and system-organ class, as established by governmental regulatory agencies.

Frequency-Classified Adverse Reactions

The most frequently reported adverse reaction, classified as Very Common, is peripheral edema (swelling). Adverse reactions designated as Common typically involve the nervous, cardiovascular, and general systems, including headache, dizziness, somnolence, flushing, palpitations, nausea, abdominal pain, fatigue, and asthenia.

Reactions categorized as Uncommon include disturbances such as tremor, hypotension, vomiting, pruritus, and rash. Very rare, but serious, adverse reactions documented in official regulatory sources include myocardial infarction, specific arrhythmias, pancreatitis, hepatitis, and severe hypersensitivity events like angioedema and Stevens-Johnson syndrome.

Contextual Safety Notes and Restrictions

Some effects, such as peripheral edema and headache, are noted to occur more often at the initiation of treatment or following a dose increase. The safety profile also includes specific restrictions: Amlodipine is contraindicated in patients with conditions such as severe hypotension, cardiogenic shock, and obstruction of the left ventricular outflow tract (e.g., high-grade aortic stenosis). Special safety considerations are noted for certain populations, including a recommended lower starting dose for older adults and patients with hepatic impairment, as the drug's clearance may be reduced in these groups.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Guidance

This section outlines the officially documented manifestations of an overdose with Alopres (Amlodipine Besylate) and the required regulatory actions for seeking emergency assistance. The information is derived strictly from government-authorized prescribing information.

Documented Manifestations and Severe Outcomes

An overdose is characterized by excessive peripheral vasodilation, resulting in marked and possibly prolonged profound hypotension (very low blood pressure) and reflex tachycardia (rapid heartbeat). Severe outcomes include the risk of shock and subsequent tissue hypoperfusion due to this extreme drop in blood pressure.

Primary Manifestation Severe Outcome Required Action
Profound Hypotension Risk of Shock Seek immediate medical attention
Reflex Tachycardia Tissue Hypoperfusion Active cardiac and respiratory monitoring

Emergency Actions and Supportive Management

Immediate medical attention must be sought for any suspected overdose. Emergency services should be contacted immediately if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Management in a clinical setting requires continuous active cardiac and respiratory monitoring and frequent blood pressure measurements. Supportive measures described in regulatory labeling include fluid administration, cardiovascular support (such as limb elevation), and, if necessary, the administration of vasopressors. Intravenous calcium gluconate is noted as an agent that may help reverse the effects of calcium entry blockade.

Therapeutic Uses of Alopres

What Alopres Treats: Main Uses and Benefits

Alopres (Amlodipine) is commonly used to provide sustained control of high blood pressure (hypertension) in adults and in children six years of age and older. This long-acting therapy is relevant in conditions presenting with systemic discomfort, including chronic stable angina and vasospastic angina. Lowering blood pressure supports general well-being during symptomatic phases and may be relevant for easing challenging symptoms. The therapeutic domains for which this medication is applied include high blood pressure, recurring chest pain, and supportive management in documented heart disease.

The medication is relevant in clinical settings marked by the recurring symptoms related to physical discomfort. It helps address these symptom clusters that may become intense or disruptive. The therapy contributes to improved comfort during periods of heightened symptoms and may assist with managing the occurrence of symptoms that interfere with daily functioning.


Quick Facts: Therapeutic Summary

Property Description
Primary Use Supports long-term management of high blood pressure (hypertension).
Symptom Relief Relevant for easing symptoms related to recurring chest pain (angina).
Clinical Context Applied in conditions marked by increased physiological stress, such as documented coronary artery disease.
Patient Benefit Helps maintain a sense of stability and assists with maintaining functional stability.

Regulatory References

  1. NIH DailyMed Overview

Eligibility and Restrictions for Use

Alopres (Amlodipine) is approved for use in adult patients and in pediatric patients aged six years and older for the treatment of hypertension. Official regulatory documents define clear population-based exclusions and restrictions to guide appropriate use.

The medicine is contraindicated and must not be used by individuals with a known sensitivity or allergy to Amlodipine or other dihydropyridine derivatives. It is also contraindicated in patients experiencing severe hypotension or cardiogenic shock.

Use is not established and is therefore not recommended for children under six years of age. Special precautions are required for older adults and patients with severe hepatic impairment, who typically require a lower initial dose due to the drug's prolonged clearance. Patients with renal impairment are generally eligible for standard initial dosing.

Regarding life stage, Amlopres is not recommended for use while breastfeeding, and official labeling advises that nursing should be discontinued during treatment. Use during pregnancy is highly restricted, considered only when the potential benefits clearly outweigh the potential risks.

What should I know about interactions with other medicines?

Alopres (Amlodipine) interactions with other medicinal products are primarily governed by its metabolic pathway through the Cytochrome P450 3A4 (CYP3A4) enzyme system in the liver. Co-administration with strong or moderate CYP3A4 inhibitors (e.g., certain antifungals like ketoconazole, or antibiotics like clarithromycin) may result in a significant increase in Amlodipine exposure, raising the risk of excessive blood pressure lowering and edema. Conversely, CYP3A4 inducers (e.g., rifampicin, St. John’s Wort) may reduce Amlodipine’s plasma concentration and effectiveness.

Documented Interaction Restrictions

Interacting Product/Category Interaction Mechanism Official Regulatory Restriction
Simvastatin (a statin) Amlodipine increases Simvastatin exposure via CYP3A4 inhibition, raising the risk of myopathy. Do not exceed 20 mg of Simvastatin daily.
Other Antihypertensives Pharmacodynamic additive effect. May cause additive blood pressure lowering, requiring careful monitoring.
Cyclosporine/Tacrolimus (Immunosuppressants) Amlodipine may increase the systemic exposure of these drugs. Monitor plasma concentrations; dose adjustment may be necessary.

Patients taking other blood pressure lowering medications should be monitored for enhanced effects. Individuals with hepatic impairment may experience reduced clearance of Amlodipine, increasing susceptibility to these interactions.

Mechanism of Action

Inhibition of Voltage-Dependent Calcium Channels

Alopres functions as a calcium channel blocker through its primary mechanism: the specific inhibition of L-type voltage-dependent calcium channels found on vascular smooth muscle and cardiac cells. This engagement falls within the domain of receptor-mediated signaling pathways that utilize calcium influx.

Modulation of Vascular Tone

By occupying and inhibiting these channels, Alopres alters the transmembrane flux of calcium ions. This reduction in Ca^2+ entry limits the amount of intracellular calcium available for the process of excitation-contraction coupling within smooth muscle cells. The resulting intracellular consequence is a signaling cascade that promotes the direct relaxation and dilation of peripheral and coronary arterial segments.

System-Level Physiological Consequence

The ultimate physiological adjustment is the reduction in systemic vascular resistance, which consequently decreases the afterload exerted on the heart. This action modulates key pathways associated with vascular contractility, leading to predictable systemic effects on blood flow dynamics.

Dosage and Administration Information

Alopres (Amlodipine Besylate) is administered via the oral route as a once-daily dose. The administration protocol mandates a standardized frequency, typically taken at the same time each day, which can be done with or without food. The medication is available in official tablet strengths of 2.5 mg, 5 mg, and 10 mg.

For most adult patients, the usual initial dose is 5 mg once daily. The standard maintenance dose range is 5 mg to 10 mg, and the absolute maximum authorized daily dose is 10 mg. Changes to the dosage must be approached slowly, requiring a period of 7 to 14 days between dose adjustments to ensure the drug reaches a stable concentration within the body before assessment.

Specific patient populations require modification of the starting regimen. For older adults and patients with impaired liver function (hepatic impairment), a lower initial dose of 2.5 mg once daily is suggested, followed by slow titration. In pediatric patients aged 6 to 17 years, the authorized dose range begins at 2.5 mg and does not exceed 5 mg daily.

If a dose is missed, it should be skipped if it is significantly closer to the next scheduled dose—for instance, if more than 12 hours late—and a double dose must never be taken to compensate. The oral tablet can be dispersed in water and consumed immediately if swallowing is difficult. The requirement for a daily, consistent dose and the defined titration interval establishes the official procedural structure for the long-term use of this medication.

Recent Clinical Evidence

Research evidence / Overview of Studies for Alopres (Amlodipine Besylate)

Evidence for Use in High Blood Pressure (Hypertension)

The research base for using Alopres in managing high blood pressure is primarily built on numerous Randomized Controlled Trials (RCTs) and large, long-term comparative studies. These studies were designed to assess changes in both the upper (systolic) and lower (diastolic) numbers of blood pressure (BP) and track the incidence of serious long-term health outcomes. Research examined measurements of blood pressure change over defined time intervals.

Studies conducted during the research phase reported measurements showing a consistent pattern of blood pressure change compared to placebo in the observed populations. Research also monitored long-term outcomes, using follow-up periods of three to six years, to track the occurrence of major cardiovascular events like stroke or heart attack in patients with hypertension. These long-term studies were often applied in research settings comparing Alopres against other active medications for hypertension.

What remains uncertain is the full long-term profile against a non-active comparator (placebo) over many years, as long-term outcome data mostly derives from comparative studies against other active agents. Furthermore, findings were mixed across specific patient subgroups, and evidence for certain groups remains insufficient, indicating that results apply only to the populations studied.

Evidence for Use in Angina and Coronary Artery Disease

Research explored the use of Alopres in conditions characterized by periods of heightened symptoms, specifically chronic stable angina (chest discomfort related to exertion) and vasospastic angina. The evidence is supported by specific placebo-controlled trials designed to evaluate how symptoms change over time. Studies monitored outcomes related to physical discomfort by measuring patients’ ability to tolerate exercise and recording the reported frequency of angina attacks.

For chronic stable angina, studies monitored outcomes reflecting daily functioning by measuring the length of time patients could exercise before symptoms appeared. Studies reported measurements related to the time until onset of symptoms during these tests compared to placebo in the studies. In the broader context of Coronary Artery Disease (CAD), large-scale randomized trials were conducted over intermediate to long periods, recording the incidence of outcomes such as the need for procedures to revascularize the heart or the frequency of hospitalizations for chest discomfort.

Research in Special Populations and Long-Term Outcomes

Research also explored the use of Alopres in certain specific patient populations, including children aged six years and older. Studies were conducted to evaluate Alopres in this pediatric group, specifically monitoring outcomes related to systemic or functional imbalance by tracking BP changes. Findings were mixed across different age subgroups, and data for certain groups remain insufficient. For older adults, specific studies examined how the medicine is processed in the body, with initial findings indicating a difference in how the body handles the drug over time.

What is Still Uncertain About Alopres's Research Record

One key limitation is that the large, long-term studies tracking the most serious outcomes (like heart attack or stroke occurrence) often compared Alopres to other medications, not to a placebo; thus, comparative evidence is lacking for a direct, long-term comparison against no active treatment. Furthermore, studies focusing on patients with documented heart disease often specifically excluded those with significant functional limitations or a reduced pumping capacity of the heart. For this reason, evidence quality varies across studies, and findings were mixed when researchers explored its use in populations with more severe functional limitations.

Frequently Asked Questions (FAQ)

Common questions about Alopres (FAQ)


Q: Does Alopres have a generic version available?

A: Yes, regulatory information confirms that Amlodipine is the established nonproprietary, or generic, name for the active ingredient in Alopres. Generic versions of this medication are widely available from various manufacturers.


Q: What is Alopres made of?

A: Official labeling lists the active ingredient as Amlodipine besylate. The tablets also contain several inactive ingredients, or excipients, such as microcrystalline cellulose, dibasic calcium phosphate anhydrous, sodium starch glycolate, and magnesium stearate.


Q: How quickly do people typically expect to see effects from Alopres?

A: According to the official product information, the concentration of the drug in the blood typically peaks between 6 and 12 hours after taking a dose. The full blood pressure-lowering effect is generally maintained for a 24-hour period with once-daily dosing. When beginning treatment, it takes about 7 to 8 days to reach a steady concentration level in the body.


Q: What is the official definition of the condition Alopres treats?

A: Amlodipine is officially indicated for the treatment of Hypertension (high blood pressure) and certain types of Coronary Artery Disease, specifically Chronic Stable Angina and Vasospastic Angina. These conditions are characterized by high arterial pressure or chest pain related to reduced blood flow and oxygen supply to the heart.


Q: Are there any specific food items to avoid while taking Alopres?

A: Official information cautions that consuming grapefruit or grapefruit juice may increase the amount of the drug in the body, potentially leading to worsened side effects. The medication can otherwise be taken with or without other food.


Q: Can I use Alopres if I have depression or anxiety?

A: Adverse reactions reported during the post-marketing period include mood changes, depression, and anxiety. Regulatory sources recommend that any patient experiencing mental health concerns seek guidance from a qualified healthcare professional.


Q: Will Alopres affect my weight?

A: Yes, changes in weight have been reported as adverse reactions in clinical studies. Both weight gain and weight decrease are listed among the reactions reported infrequently.


Q: Is it safe to stop taking Alopres suddenly?

A: Official labeling does not recommend stopping this medication suddenly. The official labeling warns that an increase in the severity of angina (chest pain) or a heart attack can occur when starting or increasing the dose in certain patients, suggesting any change in treatment should be medically supervised.


Q: Can I drink coffee while taking Alopres?

A: The official prescribing information does not list coffee or caffeine as a specific interaction. However, some common side effects of this medication, such as palpitations (fast or fluttering heartbeat) or flushing, are sometimes associated with high caffeine intake. If a patient experiences these symptoms, their healthcare provider may advise them on managing caffeine intake.


Q: Can I take over-the-counter pain relievers (like ibuprofen or naproxen) while on Alopres?

A: Official drug interaction information indicates that using Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen or naproxen, may reduce the blood pressure-lowering effect of Amlodipine. Official information indicates that a healthcare provider should be consulted before combining Amlodipine with other medications, including NSAIDs.


Q: Is Alopres a habit-forming drug?

A: The official regulatory text makes no mention of dependence, abuse, or controlled substance classification for Amlodipine. This suggests the medication is not considered habit-forming in the context of controlled substance regulations.


Q: Does Alopres affect my driving ability?

A: Regulatory warnings state that common side effects such as dizziness, somnolence (drowsiness), and fatigue may impair the ability to drive or operate machinery. Due to these potential effects, it is typically advised to observe how the medication affects them before driving or operating machinery.


Q: How should a side effect be reported to an authority like the FDA or EMA?

A: Mechanisms exist for reporting adverse reactions directly to the governmental regulatory authority, such as the FDA's MedWatch program in the U.S., or the relevant national agency in other regions. This is part of the ongoing safety monitoring of the drug.


Q: Can Alopres make me feel dizzy or light-headed?

A: Yes, dizziness is reported as a common side effect in clinical trials. Somnolence, which is a feeling of drowsiness or light-headedness, is also commonly reported. These effects are often noted to occur more frequently when starting treatment or increasing the dose.


Q: Does Alopres have a risk of serious allergic reaction?

A: Official labeling notes that Amlodipine is contraindicated (should not be used) in patients with a known sensitivity to the drug. Serious allergic reactions, including severe swelling known as angioedema, have been reported in post-marketing experience.


Q: Is Alopres safe for long-term use?

A: Clinical studies reviewed by regulatory agencies demonstrated that the drug's effectiveness in lowering blood pressure was maintained with long-term, once-daily use. Drug tolerance, where the medicine becomes less effective, was not observed in patients studied for up to one year, suggesting that loss of effectiveness was not a primary concern in these specific studies.


Q: Is Alopres safe for children?

A: Amlodipine is indicated and approved for use in pediatric patients aged 6 to 17 years for the treatment of hypertension. However, the official prescribing information notes that doses beyond a specified limit have not been studied in this population.


Q: Do I need regular check-ups while on Alopres?

A: Regulatory guidance for dose adjustments (especially in certain populations like those with liver conditions) suggests that ongoing medical supervision and monitoring of blood pressure are integral parts of therapy. This is consistent with the need to ensure the most appropriate response to the medication.


Q: Can Alopres affect my blood sugar?

A: Official adverse reaction data includes reports of hyperglycemia (high blood sugar) as a less frequent adverse reaction reported during the post-marketing experience. If a patient has concerns about blood sugar while taking this medication, they are advised to consult a qualified healthcare professional.


Q: Is there a risk of heart problems when starting Alopres?

A: Regulatory warnings indicate that an increase in the frequency, duration, or severity of angina (chest pain) or acute myocardial infarction (heart attack) can occur when beginning or increasing the dose. This risk is noted particularly in patients who have severe obstructive coronary artery disease.


Q: Will Alopres make me tired or fatigued?

A: Yes, both fatigue and somnolence (drowsiness) are reported as common adverse reactions in clinical trials. These effects are generally noted to occur more often when treatment is first initiated or the dose is increased.


Q: What is the difference between Amlodipine and Alopres?

A: Amlodipine is the internationally recognized generic name for the active chemical ingredient in the medication. Alopres is the brand name used to market this specific formulation, meaning they refer to the same drug substance.


Q: Can I take Alopres if I have a liver condition?

A: The official label advises using caution in patients with impaired hepatic function (liver condition) because the drug's clearance may be prolonged. Special considerations are outlined for patients with severe liver impairment, which includes the need for caution and potential dose modification under medical supervision.


Q: What is a 'contraindication' for a medication?

A: A contraindication is a condition or factor that officially advises against the use of a medical treatment because it may cause harm to the patient. For Amlodipine, known sensitivity or allergy to the drug is a listed contraindication.


Q: Can Alopres interact with herbal supplements?

A: Official interaction guidance notes that Amlodipine is processed by the CYP3A4 enzyme in the liver. Using certain strong CYP3A4 inhibitors, which include some herbal products, can increase the amount of the drug in the body. Because of this potential interaction, a healthcare professional would typically review the patient’s supplement use and adjust treatment as necessary.


Q: Does Alopres interact with my other blood pressure medicine?

A: Official labeling confirms that Amlodipine is approved for use either alone or in combination with other agents that lower blood pressure. Due to the potential for additive effects, any combination therapy is managed under the guidance of a healthcare professional.

How should Alopres be stored and disposed of?

Storage Requirements

Alopres (Amlodipine Besylate) tablets must be stored at controlled room temperature, typically between 59 F to 86 F (15 C to 30 C). The medication must be protected from environmental factors that compromise stability, specifically light, excess heat, and moisture. It is required to keep the container tightly closed and in a location that is kept from freezing.

Child-Safety and Handling

For safety, the medication must be stored out of the reach of children, and safety caps must always be secured. Due to moisture concerns, storage in a bathroom is prohibited.

Disposal Instructions

Unused or expired tablets should be disposed of in accordance with local requirements. The drug is not recommended for flushing. When take-back programs are unavailable, tablets should be mixed with an undesirable substance and sealed in a container before being discarded in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alopres found in:

A-Z Index: